Unlocking Secondary Packaging’s Potential to Accelerate Smart Tech Adoption and Sustainability Goals

**Title: Unlocking Secondary Packaging’s Potential to Accelerate Smart Tech Adoption and Sustainability Goals**

For decades, secondary packaging has been the quiet workhorse of pharmaceutical supply chains—functional, protective, and largely overlooked. Primary packaging, with its direct drug-contact requirements and patient-centric innovations, has commanded the lion’s share of R&D attention and capital investment. However, a convergence of regulatory pressures, supply chain digitization, and sustainability mandates is forcing contract development and manufacturing organizations (CDMOs) to reexamine this long-neglected layer. Secondary packaging is no longer merely a shipping container; it is emerging as a critical interface for smart technology integration and environmental accountability.

The implications for CDMOs are significant. As drug sponsors demand end-to-end visibility and serialization compliance, secondary packaging offers a practical, cost-effective platform for embedding sensors, RFID tags, and blockchain-enabled tracking systems. Unlike primary packaging, which must navigate complex biocompatibility and stability requirements, the secondary layer can be adapted more rapidly to accommodate digital enhancements. For CDMOs, this means an opportunity to differentiate by offering integrated solutions—combining traditional packaging services with data capture, temperature monitoring, and anti-counterfeiting technologies. Firms that invest in modular, smart-packaging workflows will be better positioned to serve clients navigating the U.S. Drug Supply Chain Security Act (DSCSA) and evolving global traceability standards.

Sustainability is another driver reshaping secondary packaging’s role. Pharmaceutical companies are under mounting pressure to reduce plastic waste and carbon footprints, yet primary packaging changes are often slow due to regulatory hurdles. Secondary packaging, by contrast, allows for faster material substitution—such as transitioning from multi-layer laminates to mono-material recyclable structures or fiber-based alternatives—without compromising drug stability. CDMOs that develop scalable, sustainable secondary packaging options can help sponsors meet corporate ESG targets while maintaining operational efficiency. This shift also opens the door to reusable and returnable packaging models for bulk intermediates, reducing waste across the supply chain.

Ultimately, the CDMO sector stands at a strategic inflection point. By elevating secondary packaging from a logistical afterthought to a value-added service layer, manufacturers can accelerate both smart technology adoption and sustainability goals. The challenge lies in balancing customization with standardization, and in building the internal capabilities to manage data integration alongside physical packaging. Those that succeed will not only meet current regulatory and environmental demands but also position themselves as indispensable partners in the next generation of pharmaceutical supply chain design.

Industry Context

This intelligence report covers the cdmo sector in US.

Data Source

Source: Contract Pharma View original